In 2020, Getein Biotech, Inc. acquired a 58.53% stake in Jingchuan Diagnosis through agreement transfer and capital increase. Three years later, Getein Biotech, Inc. and Jingchuan Diagnosis management shareholders went to court. Getein Biotech, Inc. believes that the core claims of both parties involve the PE (price-to-earnings) calculation of repurchasing subsidiary management shareholder rights. The reporter interviewed Jingchuan Diagnosis management shareholders, who denied Getein Biotech, Inc.'s statement and emphasized that they had accepted the 15 times PE pricing given by Getein Biotech, Inc. Jingchuan Diagnosis management shareholders believe that the core disagreement between the two parties is that Getein Biotech, Inc. did not have sincerity, changed the acquisition time, acquisition conditions and payment methods. When communicating with Getein Biotech, Inc., the proposed non-compete clause was 'lifetime competition restriction' in the eyes of Jingchuan Diagnosis management shareholders. Getein Biotech, Inc.'s Secretary of the Board Liu Cong told reporters that after multiple rounds of negotiations, the two sides did not reach an agreement, and many details were not finalized in the final agreement. (Meijing Net)